A Close Call: FDA’s Decision Memo On The Approval of Chelsea Therapeutics’ Northera
On February 18, FDA granted accelerated approval to Chelsea Therapeutics’ Northera (droxidopa) for neurogenic orthostatic hypotension. The review was difficult, generating a “complete response” letter and a formal dispute resolution after the first cycle, and a negative primary review on the second go-around. The final decision by Office of Drug Evaluation I Director Ellis Unger was to overrule the division director and approve the application. His approval memo stands out for its detailed analysis of the arguments “pro” and “con,” and ultimately as a statement in support of extra flexibility for rare disease drugs. Here is the conclusion of his memo.
Dr. Targum, the cross-discipline team leader, provided a superb summary of the evidence of effectiveness, and her views are summarized as follows:
The applicant submitted 4 studies in the NDA: 301, 302, 303, and 306B. Two of them, Studies 301 and 306B,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
The US FDA ended efforts to regulate lab-developed tests as medical devices for now when it did not appeal a decision from the Eastern District of Texas that tossed out the agency's final rule.
The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.
CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.
The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.
CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.
The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.
